RÉSUMÉ
<p><b>OBJECTIVE</b>To analyze the clinical features of clonal evolution of acquired aplastic anemia (AA) into myelodysplastic syndrome/acute myeloid leukemia (AML) and review of literatures.</p><p><b>METHODS</b>AA developing MDS/AML patients between December 1994 and December 2011 enrolled into this study to analyze their clinical characteristics.</p><p><b>RESULTS</b>During the median follow-up of 49(15-97) months, 19 patients evolved to MDS/AML, of whom 10, 8 and 1 were from VSAA, SAA and NSAA subgroups, respectively. The median G-CSF therapy was 270(29-510) days. There were monosomy 7 in 11(57.9%) of 19 patients with AA evolved to MDS/AML. The median AA evolved to MDS/AML was 33(11-88) months. The median MDS/AML transformation in responders (54.2 months) was significantly longer than of non-responders (25.7 months, P<0.01).</p><p><b>CONCLUSION</b>AA patients could evolved into MDS/AML concomitant with abnormal karotype and worse prognosis.</p>
Sujet(s)
Humains , Anémie aplasique , Délétion de segment de chromosome , Chromosomes humains de la paire 7 , Facteur de stimulation des colonies de granulocytes , Leucémie aigüe myéloïde , Syndromes myélodysplasiquesRÉSUMÉ
Objective To explore the effects of hydroxyurea(HU) combined chemotherapy in treating hyperleukocytosis acute leukemia(HAL).Methods All the 21 patients were divided into two groups randomly.The patients of experiment group were treated by HU,(0.1g tid po),continuing 3-7 days,along with allopurinol(200 mg tid po).The 18 patients of controlled group were treated only by chemotherapy.Results The results showed the majority(57.1%) patients were of completely remiss(CR),the proportions of partly remission(PR) and no remission(NB) were 19.0% and 23.8%.To- tal remission rate was 76.1%.Two patients died early(9.5%.In the controlled group,the rate of CR,PR,NR were 16. 7%,33.3%,and 50%.Four patients died early(22.4%).Conclusion The HU combined chemotherapy had higher re- mission rate than that of chemotherapy in treating HAL.